ArticleInternational urology and nephrology2026
Beyond VI-RADS: incremental value of quantitative mpMRI measurements for identifying muscle-invasive bladder cancer.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesTo assess whether simple quantitative multiparametric magnetic resonance imaging (mpMRI) measurements add diagnostic value to Vesical Imaging-Reporting and Data System (VI-RADS) scores for preoperative identification of muscle-invasive bladder cancer (MIBC).
methodsTumor diameter, tumor-wall contact length, and VI-RADS scores were evaluated. The primary outcome was pathological MIBC. Diagnostic performance was assessed using receiver operating characteristic analysis, logistic regression, bootstrap internal validation, reclassification indices, calibration, and decision curve analysis.
resultsThe combined model including VI-RADS score (overall), average tumor diameter, and average tumor-wall contact length achieved an AUC of 0.808 (95% CI 0.739-0.876), compared with 0.769 (95% CI 0.702-0.836) for VI-RADS alone (DeLong P = 0.023). Continuous net reclassification improvement was 0.370 (95% CI 0.046-0.734), and integrated discrimination improvement was 0.034 (95% CI 0.003-0.116). Decision curve analysis suggested a modest gain in net benefit across threshold probabilities of 0.20-0.80.
conclusionQuantitative mpMRI measurements provided a modest, statistically significant but clinically limited incremental value beyond VI-RADS for identifying MIBC, although VI-RADS remained the main predictor.
Indexed as
Identifiers
42430096What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.